BioCardia, Inc. (BCDA)
- Previous Close
0.3658 - Open
0.3789 - Bid 0.2636 x 200
- Ask 0.4836 x 200
- Day's Range
0.3690 - 0.3840 - 52 Week Range
0.3200 - 2.9200 - Volume
29,240 - Avg. Volume
351,038 - Market Cap (intraday)
10.118M - Beta (5Y Monthly) 1.49
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5500 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
www.biocardia.comRecent News: BCDA
Performance Overview: BCDA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCDA
Valuation Measures
Market Cap
10.12M
Enterprise Value
10.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.72
Price/Book (mrq)
--
Enterprise Value/Revenue
21.66
Enterprise Value/EBITDA
-0.89
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-113.89%
Return on Equity (ttm)
-703.62%
Revenue (ttm)
477k
Net Income Avi to Common (ttm)
-11.57M
Diluted EPS (ttm)
-0.5500
Balance Sheet and Cash Flow
Total Cash (mrq)
1.1M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.03M